RE: Dilution worries... is that why we're in red?26 Feb 2021 16:17
Hi Phil
This was the statement from Duncan from the RNS On 22/10/20. "We expect that a NASDAQ Listing will allow 4D to capitalise on increased interest from US healthcare investors in recent years and provide access to a much larger pool of specialist capital, thereby increasing our global profile and exposure. NASDAQ is an attractive market for growing, innovative biotech companies. The Merger will accelerate and de-risk 4D's admission to NASDAQ, while providing immediate access to additional funds to support our pipeline."
It was my understanding that raising funds was one of the main reasons to list on the NASDAQ.
Regards
Craig